Terms: = Germ cell tumor AND MLH1, COCA2, 4292, ENSG00000076242, hMLH1, FCC2, HNPCC2, P40692, MGC5172, HNPCC
330 results:
1. Exploring the combined anti-cancer effects of sodium butyrate and celastrol in glioblastoma cell lines: a novel therapeutic approach.
Kartal B; Denizler-Ebiri FN; Güven M; Taşpınar F; Canpınar H; Çetin S; Karaduman T; Küççüktürk S; Castresana J; Taşpınar M
Med Oncol; 2024 Mar; 41(5):97. PubMed ID: 38532150
[TBL] [Abstract] [Full Text] [Related]
2. Histone H3K9 Lactylation Confers Temozolomide Resistance in Glioblastoma via LUC7L2-Mediated mlh1 Intron Retention.
Yue Q; Wang Z; Shen Y; Lan Y; Zhong X; Luo X; Yang T; Zhang M; Zuo B; Zeng T; Lu J; Wang Y; Liu B; Guo H
Adv Sci (Weinh); 2024 May; 11(19):e2309290. PubMed ID: 38477507
[TBL] [Abstract] [Full Text] [Related]
3. Predictive tissue markers in testicular germ cell tumors: Immunohistochemical expression of mlh1 and REV-7 proteins.
Spinos T; Zografos E; Koutsoukos K; Zagouri F; Kosmas C; Driva TS; Goutas D; Gakiopoulou C; Agrogiannis G; Theochari E; Tzavara C; Lazaris AC
Int Urol Nephrol; 2024 Jun; 56(6):1887-1898. PubMed ID: 38285100
[TBL] [Abstract] [Full Text] [Related]
4. SOMATIC DEFICIENT MISMATCH REPAIR ASSESSED BY IMMUNOHISTOCHEMISTRY AND CLINICAL FEATURES IN BRAZILIAN GLIOBLASTOMA PATIENTS.
Yamada CAF; Malheiros SMF; Do Amaral LLF; Lancellotti CLP
Exp Oncol; 2023 Dec; 45(3):297-311. PubMed ID: 38186025
[TBL] [Abstract] [Full Text] [Related]
5. Both mlh1 deficiency and BRAFV600E mutation are a unique characteristic of colorectal medullary carcinoma: An observational study.
Kaneko M; Nakashima M; Sugiura K; Ishida N; Tamura S; Tani S; Yamade M; Hamaya Y; Osawa S; Tatsuta K; Kurachi K; Baba S; Iwashita Y; Arai T; Sugimura H; Maekawa M; Sugimoto K; Iwaizumi M
Medicine (Baltimore); 2023 Sep; 102(38):e35022. PubMed ID: 37746995
[TBL] [Abstract] [Full Text] [Related]
6. Glioma arising in the setting of mismatch repair deficiency-rare or are we missing it?
Goyal A; Rao S; Rishi KS; Ramaswamy V; Sadashiva N; Santosh V
Childs Nerv Syst; 2024 Jan; 40(1):233-237. PubMed ID: 37733272
[TBL] [Abstract] [Full Text] [Related]
7. The antagonistic effects of temozolomide and trichostatin a combination on MGMT and DNA mismatch repair pathways in Glioblastoma.
Güven M; Taşpınar F; Denizler-Ebiri FN; Castresana JS; Taşpınar M
Med Oncol; 2023 Jul; 40(8):223. PubMed ID: 37403006
[TBL] [Abstract] [Full Text] [Related]
8. Histopathologic Features for Overall Survival in Merkel cell Carcinoma: A Case Series with Intact Mismatch Repair Protein Expression.
Kestel S; Ogut B; Inan MA; Erdem O
Turk Patoloji Derg; 2023; 39(3):169-178. PubMed ID: 37350641
[TBL] [Abstract] [Full Text] [Related]
9. Mismatch Repair Deficiency and Lynch Syndrome Among Adult Patients With Glioma.
Benusiglio PR; Elder F; Touat M; Perrier A; Sanson M; Colas C; Guerrini-Rousseau L; Tran DT; Trabelsi N; Carpentier C; Marie Y; Adam C; Bernier M; Cazals-Hatem D; Mokhtari K; Tran S; Mathon B; Capelle L; Dhooge M; Idbaih A; Alentorn A; Houillier C; Dehais C; Hoang-Xuan K; Cuzzubbo S; Carpentier A; Duval A; Coulet F; Bielle F
JCO Precis Oncol; 2023 May; 7():e2200525. PubMed ID: 37262394
[TBL] [Abstract] [Full Text] [Related]
10. Lynch syndrome-associated chordoma with high tumor mutational burden and significant response to immune checkpoint inhibitors.
Shinojima N; Ozono K; Yamamoto H; Abe S; Sasaki R; Tomita Y; Kai A; Mori R; Yamamoto T; Uekawa K; Matsui H; Nosaka K; Matsuzaki H; Komohara Y; Mikami Y; Mukasa A
Brain Tumor Pathol; 2023 Jul; 40(3):185-190. PubMed ID: 37086325
[TBL] [Abstract] [Full Text] [Related]
11. Mismatch repair-deficient glioma with spatially distinct IDH-mutant and IDH-wild type components arising in the setting of Lynch syndrome.
Tan H; Nerison C; Stateler C; Bowden SG; Raslan AM; Ambady P; Barajas RF; Wood MD
Cold Spring Harb Mol Case Stud; 2023 Apr; 9(2):. PubMed ID: 37076313
[TBL] [Abstract] [Full Text] [Related]
12. Predictive biomarkers of immunotherapy response with pharmacological applications in solid tumors.
Kovács SA; Fekete JT; Győrffy B
Acta Pharmacol Sin; 2023 Sep; 44(9):1879-1889. PubMed ID: 37055532
[TBL] [Abstract] [Full Text] [Related]
13. Renal cell Carcinoma Unclassified with Medullary Phenotype in a Patient with Neurofibromatosis Type 2.
Sarkar S; Throckmorton W; Bingham R; Msaouel P; Genovese G; Slopis J; Rao P; Sadighi Z; Herzog CE
Curr Oncol; 2023 Mar; 30(3):3355-3365. PubMed ID: 36975468
[TBL] [Abstract] [Full Text] [Related]
14. Molecular profiling of primary uveal melanoma: results of a Polish cohort.
Kowalik A; Karpinski P; Markiewicz A; Orlowska-Heitzman J; Romanowska-Dixon B; Donizy P; Hoang MP
Melanoma Res; 2023 Apr; 33(2):104-115. PubMed ID: 36719926
[TBL] [Abstract] [Full Text] [Related]
15. Cerebral developmental venous anomalies in children with mismatch repair deficiency.
Kara B; Paksoy Y; Çağlayan AO; Seher N; Akbaş H; Köksal Y
Turk J Pediatr; 2022; 64(6):1106-1116. PubMed ID: 36583892
[TBL] [Abstract] [Full Text] [Related]
16. Case report: Complete response to pembrolizumab in a liver metastatic colon adenocarcinoma patient with a novel likely pathogenic germline MSH2 mutation.
Xu Y; Li Q; Zhao J; Ni X; Li P; Hu W
Front Immunol; 2022; 13():1064488. PubMed ID: 36518767
[TBL] [Abstract] [Full Text] [Related]
17. The genetic alterations of rectal neuroendocrine tumor and indications for therapy and prognosis: a systematic review.
Li K; Liu Y; Han J; Gui J; Zhang X
Endocr J; 2023 Feb; 70(2):197-205. PubMed ID: 36403965
[TBL] [Abstract] [Full Text] [Related]
18. Establishment and characteristics of GWH04, a new primary human glioblastoma cell line.
Cheng F; Wan X; Wang B; Li Y; Peng P; Xu S; Han C; Mao F; Guo D
Int J Oncol; 2022 Nov; 61(5):. PubMed ID: 36169178
[TBL] [Abstract] [Full Text] [Related]
19. PARP3 supervises G9a-mediated repression of adhesion and hypoxia-responsive genes in glioblastoma cells.
Nguekeu-Zebaze L; Hanini N; Noll A; Wadier N; Amé JC; Roegel L; Dantzer F
Sci Rep; 2022 Sep; 12(1):15534. PubMed ID: 36109561
[TBL] [Abstract] [Full Text] [Related]
20. Molecular characterization of gastric adenocarcinoma diagnosed in patients previously treated for Hodgkin lymphoma or testicular cancer.
Rigter LS; Snaebjornsson P; Rosenberg EH; Altena E; van Grieken NCT; Aleman BMP; Kerst JM; Morton L; Schaapveld M; Meijer GA; van Leeuwen FE; van Leerdam ME;
PLoS One; 2022; 17(7):e0270591. PubMed ID: 35877698
[TBL] [Abstract] [Full Text] [Related]
[Next]
